Viral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and/ or delayed neurological complications. At the actual context of the pandemicCoronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmedsince in 85% of COVID-19 patients, present neurological symptoms, including anosmia,ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memoryand/or behavioral disorders.However, these neurological manifestations are not well studied and their radiologicalfeatures are not well described. It is therefore important to assess these potentialneurological complications in COVID-19 patients. To the investigator knowledge, there isno previous study in the literature describing spectral brain changes in COVID +patients. Thus, the goal of this work is to describe the radiological semiology using MRIand particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation ofacute and / or delayed brain damage in COVID + patients presenting a neurologicalmanifestations that are initially related to the cranial nerves damage.
Other: Magnetic Resonance Spectroscopy (MRS).
This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal
allowing to measure under curves areas, amplitudes, ratios and concentrations of various
metabolites contained in a biological tissue, in addition to water and lipids. This
offers the possibility, in addition to the contribution of MRI imaging, to better
characterize pathological processes (inflammatory, infectious, etc.) through spectral and
metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will
be carried out with a mono-voxel spectroscopy using a PRESS [Point RESolved Spectroscopy]
sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE
of 288 ms.
Inclusion Criteria:
- Major COVID-19 patient (≥18 years old)
- COVID-19 patient presenting at least one the neurological manifestations:
anosmia, ageusia, periorbital pain, dizziness, fatigue, moderate headache, moderate
memory and behavioral disorders.
- Patient who have signed an informed consent form for the study
Exclusion Criteria:
- Patient under guardianship or curators or under judicial protection
- Pregnant and breastfeeding women
CHU Amiens
Amiens, France